Menon Nikita, Mutinta Deasy Anne, Woo Kellan, Tarabishi Jalal, Chan Eugene Yu-Hin, Kang Kristopher, Carwana Matthew, Nama Nassr
Vancouver-Fraser Medical Program, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia.
Department of Pediatrics, BC Children's Hospital, University of British Columbia, Vancouver, British Columbia.
Paediatr Child Health. 2023 Jun 13;28(7):411-416. doi: 10.1093/pch/pxad030. eCollection 2023 Nov.
Current guidelines by the Canadian Paediatric Society on treating urinary tract infections (UTIs) exclude infants ≤ 60 days old. There is considerable practice variability in this age group, especially around the optimal duration of parenteral antibiotics. The study aimed to assess local practice patterns, and the safety of a short course (≤3 days) of parenteral antibiotics in young infants.
In this retrospective cohort study, 95 infants (≤60 days) with confirmed UTIs were identified at British Columbia Children's Hospital. Patients receiving short (≤3 days) and long (>3 days) duration of parenteral antibiotics were compared. Outcomes of interest included urinary tract infection recurrence within 30 days, hospital length of stay (LOS), representation, and readmission.
Twenty infants (21%) received a short course of parenteral antibiotics. These infants were older (median 47 days versus 28 days) and non-bacteremic. Urinary tract infection recurrence was identified in 8 patients (8%), of which 7 were treated with a long duration (P = 1.0). Patients treated with a short duration had a significantly shorter LOS, with a mean difference of 4.21 days [95% CI: 3.37 to 5.05] (P < 0.001). All five (5%) bacteremic patients were treated exclusively with parenteral antibiotics.
In a Canadian setting, a short course of parenteral antibiotics is safe in young, non-bacteremic infants with UTIs. Despite substantial evidence, local practice patterns suggest a tendency towards prescription of long courses, providing an opportunity for quality improvement.
加拿大儿科学会关于治疗尿路感染(UTIs)的现行指南将60日龄及以下的婴儿排除在外。该年龄组的治疗实践存在很大差异,尤其是在肠外抗生素的最佳使用时长方面。本研究旨在评估当地的治疗实践模式,以及肠外抗生素短疗程(≤3天)用于小婴儿的安全性。
在这项回顾性队列研究中,不列颠哥伦比亚儿童医院确定了95例确诊UTIs的60日龄及以下婴儿。比较接受短疗程(≤3天)和长疗程(>3天)肠外抗生素治疗的患者。感兴趣的结局包括30天内尿路感染复发、住院时间(LOS)、再入院和再次就诊。
20例(21%)婴儿接受了短疗程肠外抗生素治疗。这些婴儿年龄较大(中位年龄47天对28天)且无菌血症。8例患者(8%)出现尿路感染复发,其中7例接受了长疗程治疗(P = 1.0)。接受短疗程治疗的患者住院时间明显较短,平均差异为4.21天[95%CI:3.37至5.05](P < 0.001)。所有5例(5%)菌血症患者均仅接受肠外抗生素治疗。
在加拿大的环境中,短疗程肠外抗生素用于患有UTIs的年幼、无菌血症婴儿是安全的。尽管有大量证据,但当地的治疗实践模式显示出倾向于开具长疗程处方的趋势,这为质量改进提供了机会。